Skip to content
AP Psychology · Biological Bases of Behavior

Acetylcholine

Acetylcholine appears in 3 reviewed AP Psychology questions and sits in Biological Bases of Behavior. Below are worked examples showing exactly how the exam tests it, with the answer marked and every distractor explained.

Acetylcholine (ACh) is a neurotransmitter that makes skeletal muscles contract and supports learning and memory in the brain. After it binds, the enzyme acetylcholinesterase breaks it down in the synapse.

Why it matters

ACh links brain chemistry to behavior you can see, such as movement and memory. Its loss in Alzheimer's disease shows how one transmitter can affect memory.

How the exam tests it

Expect drug-mechanism questions. A cholinesterase inhibitor blocks the enzyme that breaks ACh down, so more ACh stays in the synapse to bind with receptors.

Don’t confuse it with

Students confuse it with dopamine, but dopamine is tied to reward and smooth movement (Parkinson's), while ACh is tied to muscle contraction and memory (Alzheimer's).

Acetylcholine in real questions

Example 1Harder
A patient with Alzheimer's disease is found to have reduced acetylcholine (ACh) in the brain. A treatment that prevents the breakdown of acetylcholine in the synapse would be classified as which type of drug?
  1. AA MAOI, because monoamine oxidase degrades acetylcholine in the synapse, so blocking that enzyme would increase ACh levels
  2. BA cholinesterase inhibitor, because it blocks the enzyme that breaks down ACh, increasing ACh availabilityCorrect
  3. CA dopamine antagonist, because it prevents dopamine from binding to its receptor and allows acetylcholine to compensate
  4. DAn ACh reuptake inhibitor, because it prevents the presynaptic reabsorption of ACh, leaving more in the synaptic cleft

Why B is right

Acetylcholinesterase is the enzyme that breaks down acetylcholine in the synaptic cleft. Cholinesterase inhibitors (like donepezil/Aricept, rivastigmine) block this enzyme, preventing ACh degradation and leaving more ACh available to bind to receptors. This temporarily improves cholinergic transmission and can modestly improve memory and cognitive function in Alzheimer's patients. They are among the most common pharmacological treatments for Alzheimer's disease.
Why the other 3 choices miss
A
Incorrect because MAO (monoamine oxidase) specifically degrades monoamine neurotransmitters (dopamine, serotonin, norepinephrine), not acetylcholine; MAOIs would not increase ACh levels; the enzyme that breaks down ACh is acetylcholinesterase.
C
Incorrect because dopamine antagonists block dopamine receptors; they have no direct effect on acetylcholine levels and are not used to treat Alzheimer's disease (which involves acetylcholine deficiency, not dopamine excess).
D
Incorrect because there is no clinically established acetylcholine reuptake inhibitor used in the way that SSRIs block serotonin reuptake; acetylcholine clearance from the synapse is primarily accomplished by enzymatic degradation (by acetylcholinesterase), not by reuptake transporters; the correct treatment approach is to block the enzyme.

Studied alongside

Other concepts from Biological Bases of Behavior.